source
- Lilly's retatrutide outperforms Ozempic in weight loss and blood sugar reduction in head-to-head diabetes trialEli Lilly reported that its experimental drug retatrutide showed greater efficacy than Novo Nordisk’s Ozempic in a large diabetes trial. After 80 weeks, participants receiving the highest dose of…
- Lilly's retatrutide outperforms Ozempic in phase 3 trial, cutting blood sugar and weight moreEli Lilly tested its triple-G candidate retatrutide against Novo Nordisk's Ozempic (semaglutide) in an open-label phase 3 study involving about 1,300 adults with type 2 diabetes whose glucose was n…